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iNTRoDuCTioN
The topic may be approached by defining the 
concept of anaesthesia, a term introduced by Oliver 
Wendell Holmes for defining the elimination of sur-
gical pain, characterised by immobility, eliminating 
pain, amnesia and lack of consciousness, effects 
provoked by using anaesthetic agents reversibly 
affecting different areas of the central nervous sys-
tem (CNS). These conditions were successfully met 
for the first time on the 16th of October 1846 in the 
Massachusetts Hospital when Dr. William Morton1 
administered ether by inhalatory route to a patient 
for the removal of a mass from the neck, a landmark 
for modern medicine, especially in surgical areas. 
New anaesthetics have been developed since then 
and attempts made to understand their mechanism 
of action (MOA) for ascertaining the components of 
anaesthetics.  
 Some investigators have tried to describe anaes-
thetics’ MOA, such as Claude Bernard who described 
how the effect of anaesthetics could be caused via a 
common target for action in the CNS. Around 1900 
Meyer and Overton, independently and then together, 
described the power of anaesthetics according to their 
solubility in lipids, establishing the Meyer-Overton 
hypothesis indicating cellular lipid membranes as 
being the main target for anaesthetic action.2
In spite of anaesthesiology having been practised 
for a broad diversity of surgical procedures from this 
moment on, it has only been since three decades ago 
that the mechanisms by which these drugs act and 
are reverted have been discovered due to scientific 
advances in molecular biology.2-3
Molecular biology, which focuses on studying life 
at molecular level, integrates several sciences such 
as genetics and genetic engineering for understan-
ding different cellular systems’ interactions inclu-
ding DNA–RNA relationships, proteins, metabolism 
and how all these interactions are related for the 
functioning of the cell.4 - 6
Important developments in molecular biology, 
such as genetic mapping, point mutations and deve-
loping knockout and knock-in mice (in which a gene 
is blocked or activated for understanding determined 
proteins’ function in their absence), have led to unders-
tanding molecular biology’s vertiginous advances.4
ANAESTHETiCS’ PHySiologiCAl 
mECHANiSmS
Understanding anaesthetics’ MOA is made sim-
pler when it is studied by describing how anaesthe-
tics act on each of their components (immobility, 
hypnosis, lack of consciousness, amnesia).5
Immobility
Eliminating movement as a response to pain is 
primarily mediated at spinal cord level. At brain 
level anaesthetics selectively inhibit many sites, 
including the thalamus, reticular substance, cor-
tical regions (motor and sensory) and subcortical 
regions.  However, there is no definitive evidence 
about specific regions which are the target in the 
CNS for inhaled anaesthetics.3 
Research using knockout mice has led to gam-
ma-aminobutyric acid (GABA)A α2 receptors being 
related to relaxation related to diazepam101 and the 
GABAA β3 subunit being related to immobility cau-
sed by propofol, etomidate and halothane.102 No re-
lationship with a single receptor has been found for 
inhaled anaesthetics since several interaction sites 
have been demonstrated. A 20% increase in minimal 
alveolar concentration (MAC) for isoflorane and se-
voflorane can be observed when blocking GABAA β3 
receptors; when glycine receptors are blocked there 
is a 20% increase in MAC; a 30% increase is obtai-
ned by blocking NMDA receptors and potassium 
channel TREK-1. The foregoing observations lead to 
it being thought that immobility probably cannot be 
related to a single type of receptor.3-4-5-9-15
Sedation and hypnosis
Even though sedation has been mostly defined as 
a decreased level of consciousness, reduced motor 
activity, altered speech, hypnosis and lack of respon-
se to verbal stimuli, correlation at molecular level 
is similar.  However, a sedative effect has been im-
plicated with cortical structures and hypnosis with 
the thalamus at neuroanatomical level. Sedation 
and hypnosis have been related to the inhibition of 
GABA receptors, mainly β2 and β3. Research has 
been fundamentally centred on propofol and eto-
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midate with their action on these receptors mainly 
being located in the neocortex and the thalamus. 
Even though different studies with electroencepha-
lography and positron emission images under the 
effect of sedation and hypnosis have demonstra-
ted an overall decrease in cerebral consumption 
of glucose, this has mainly been observed in the 
aforementioned regions.33-34 Benzodiazepine action 
is related to GABA receptor α1, α2, α3, α5 and β2 
subunits, having different affinities according to the 
benzondiazepine used, thereby bestowing different 
powers; this has led to new benzodiazepines (i.e. 
bretazenil and imidazenil) being developed according 
to their affinity for subunits.7-8
Barbiturates cause sedation and hypnosis by ac-
ting on the GABA β3 receptor; at low concentrations 
this improves receptor functioning whilst increasing 
the concentration favours chloride entry even more 
without the need for binding to the receptor’s subu-
nit, favouring so-called “barbituric coma”.35-14
Amnesia - memory
It is known that the reticular activating system, 
the thalamus, the bridge, the tonsils and the hi-
ppocampus also have areas which are involved in 
memory, learning, cognition, sleep and attention. 
However, even though sleep and anaesthesia are 
clearly different states, the networking of the subcor-
tical neurons involved in sleep could become affected 
by anaesthetics. The tuberomamillar nucleus of 
the hypothalamus, modulated by GABA (especially 
by interactions between it and its receptor’s α5 
subunit), is related to states of sleep produced by 
intravenous and inhaled agents’ sedative action. 
Anaesthesia-induced lack of consciousness is con-
sistently associated with uncoupling the brain’s 
posterior-anterior and interhemispherical electrical 
connection. In clinical practice this state is associa-
ted with the suspension of counting by the patient 
during anaesthetic induction.2-3
ANAESTHETiCS’ molECulAR mECHANiSmS 
lipid action
It is known that general anaesthetics interact 
with lipid membranes, these being fundamental 
components of all cells according to Meyer and 
Overton; this theory has been used for explaining 
anaesthetic action at neuron level. Such rule re-
lates to anaesthetics’ liposolubility, in the sense 
that an anaesthetic agent becomes dissolved in the 
membranes thereby altering neuronal functions. 
However, recent studies have demonstrated that 
increased temperature and substances such as n-
alcohols and n-alkanes provoke the same changes in 
the membrane without producing anaesthesia.  An 
important role has been found for protein receptors 
due to developments in a molecular biology.13-14 
Protein action
Ion channels are proteins which regulate the flow 
of ions through the cytoplasmic membrane, being 
a variety of channels modulating a cell’s electrical 
activity. They are related to anaesthetics’ physiologi-
cal action, such channels being sensitive to several 
inhaled and intravenous anaesthetics.6-13
Ion channels are sensitive to volatile and intra-
venous anaesthetics at an effective clinical con-
centration including the two “cysteine-loop” super 
families containing nicotinic acetylcholine receptors, 
serotonin type 3, GABAA and glutamate glycine 
receptors which are activated by N-methyl-D-aspar-
tate (NMDA) or alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA). Other channels 
involve potassium, especially TREK-1.14-22-24
gABA receptor
Gamma-aminobutyric acid (GABA) is the main 
cerebral inhibitory neurotransmitter; each recep-
tor is a very complex heteromeric transmembrane 
protein which opens a permeable pore to Cl in re-
sponse to the GABA ligand.2 Rapid inhibition ino-
tropic GABAA GABAC receptors and slow inhibition 
metabotropic GABAB Ca++permeable receptors have 
been recognised. The receptor is mapped on gene 
1 of chromosome Gp21.3 in the HLA class I region, 
close to the HLA-F5 gene; however, there is genetic 
expression for each receptor subtype.16-17
GABA synthesis, at the presynaptic site, begins 
from glutamate which is carboxylated by glutamic 
acid carboxylase. GABA, in turn, is degraded by 
GABA-transaminase (GABA-T) converting it to suc-
cinic semialdehyde which is metabolised by succinyl 
semialdehyde dehydrogenase to succinic acid. GABA 
is stored in the presynaptic vesicles and released to 
the exterior like other neurotransmitters by calcium-
modulated action, where cytosol can also be cap-
tured by a transporter. On the postsynaptic side, 
GABA presents a pentameter structure consisting 
of five subunits of alpha, beta and gamma varieties 
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where receptor activator sites are found, provoking 
chloride influx via the ions channels, hyperpolari-
sing the cell and impeding excitability.6 
Evidence has been presented that there are diffe-
rent sites in the GABA receptor subunits specifically 
recognising medicaments such as barbiturates, 
agonist (midazolam, diazepam) and antagonist 
(flumazenyl) benzodiazepines (mainly subunit α) 
from propofol, mainly acting at subunit β, β2 and 
β3 level, respectively. They are used in experimental 
work with laboratory animals. All these substances 
can modulate GABA action.
Clinical practice has shown that the CNS is 
the target organ for benzodiazepines, barbiturates 
and inhaled anaesthetics. However, it should be 
stressed that these drugs were developed before 
the diversity of existing GABA receptor subtypes 
became understood. New research will surely lead 
to a better understanding of the roles which each 
GABAA receptor subunit plays regarding the action 
of anaesthetics.16-18-19-20
gABA receptor formation 
The GABA receptor has five different subunits: 
alpha, beta, gamma, delta and epsilon; the alpha 
subunit has 6 isoforms, beta 4, gamma 3, delta 1 
and epsilon 2.
Five subunits must be combined to form chlorine 
channels; each subunit’s composition changes affi-
nity for additional allosteric sites and the efficacy of 
the GABA agonist site. There are four transmembrane 
domains for each subunit (M1, M2, M3 and M4) ha-
ving hydrophobic properties leading to their inclusion 
in the lipid bilayer. Nineteen combinations have been 
found in the CNS to date, the most frequently occu-
rring ones being α1β2γ2 (60% of GABAα receptors), 
α1β3γ1 (15%) and α3βnγ2 (10 – 15%).19-20
Clinical experimentation with gABAa
Reduced immobilisation response for the δ subu-
nit in knockout mice has only been demonstrated 
with pregnenolone but not for anaesthetics such as 
phenobarbital or etomidate, thereby demonstrating 
that this subunit plays a more extrasynaptic role. 
Blocking the β3 subunit caused a drop in the level 
of hypnosis induced by etomidate and diazepam 
and partly in immobility caused by halothane, en-
fluorane and etomidate.
Experiments with point mutations have also de-
monstrated important effects. A 50% decrease in the 
effect of etomidate and propofol has been demons-
trated by changing the position of a methionine for 
an asparagine in the β subunit chain.18-21
Changes in subunit α have also been demonstra-
ted to have had many effects: the α1 subunit with 
anterograde amnesia and α2 with anxiolysis; myo-
relaxant action is related to subunits α2 and α3.
It has been demonstrated that blocking β2 and β3 
for inhaled anaesthetics could cause a 30% increase 
in MAC, thereby causing immobility with halothane 
and enfluorane.21
oTHER ioN CHANNElS 2
Glycine receptors
Glycine receptors are mainly chlorine-mediated 
inhibition receptors which are located throughout 
the CNS, but mainly in the spinal medulla. They 
are formed by a pentameric channel: 3 α subunits 
having 4 subtypes and 2 β subunits having 3 subu-
nits (few studies are available).
Their relationship with anaesthetics has been 
described, mainly with 20%-55% inhaled anaes-
thetic-mediated immobility for isoflorane and 20% 
for halothane, MAC becoming increased when they 
are blocked.25-3
glutamate receptors
Glutamate is the main CNS exciter neurotransmit-
ter, exercising its action via metabotropic and inotro-
pic receptors. It was described as a neurotransmitter 
more 40 years ago, being related to multiple neuronal 
functions. There are also pre- and post-synaptic 
receptors, pre-synaptic receptors mainly being me-
tabotropic and post-synaptic ones inotropic.
There are 3 types of inotropic receptor: NMDA, 
AMPA and kainate. They are so described due to 
their exogenous ligands, each one offering different 
types of permeability for Na and Ca.
The large diversity of glutamate receptors in 
the CNS has led to difficulty in establishing their 
relationship with anaesthetics. Studies have shown 
how nitrous oxide, xenon and ketamine are potent 
glutamate receptors antagonists (especially AMPA 
receptors). NMDA receptors are especially antago-
nised by nitric oxide and experimental studies have 
shown how isoflorane interacts with GLuR6 kainate 
receptor subunits inhibited at medullar level, the-
reby causing increased MAC. AMPA receptors and 
different subunits have been related to xenon’s 
ability to induce immobility.3-4-26
Serotonin receptors
Serotonin is a neurotransmitter which is secreted 
by many cells including neurons, chromafine cells 
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from the gastrointestinal system and platelets. They 
are related to many functions, including neurotrans-
mission in the enteric system and inhibiting many 
stimuli in the CNS related to controlling emotions, 
sleep and temperature in several CNS nuclei.
The main member of the serotonin receptor fa-
mily is the serotonin 5-HT3subtype which can be 
affected in different ways since it can be boosted 
by halogenates or can be inhibited by barbiturates 
or ketamine. Studies on with experimental animals 
which have been given specific serotonin capture in-
hibitors in determined cerebral nuclei have reported 
an increase in MAC necessary for causing immobi-
lity. Serotonin receptors are related to an altered 
state of consciousness with barbiturates.3-27
voltage-dependent potassium channels
Amongst ion channels, those for potassium have 
the greatest phylogenetic diversity. Potassium flow 
via these pore-forming proteins plays a relevant role 
in cell physiology; for example, the high permeability 
at rest to this ion produces the potential for action 
at rest and contributes towards regulating cellular 
volume in this state. There are 3 large families of 
potassium channels according to their amino acid 
sequence homology: 
a- Family of 1 pore and 6 transmembrane seg-
ments;
b- One pore and 2 transmembrane segments; and
c- Two pores and 8 segments, the TREK and 
TASK channels, strongly implicated in the action of 
anaesthetics, belonging to the last family. TREK-1 
channels are related to the immobility caused by in-
haled anaesthetics at medullar level. TASK channels 
related to base ganglions are related to immobility 
caused by propofol.28-29
Nicotinic acetylcholine receptors
Nicotinic receptors are cholinergic ion channels 
(i.e. they are able to respond to  a chemical mediator 
such as acetylcholine. They are so called because 
they can be activated by nicotine, unlike receptors 
which are activated by muscarine. 
Nicotinic receptor studies in anaesthesiology have 
been related to nearly all anaesthetics (both inhaled 
and intravenous ones) causing their inhibition.
Studies carried out on the Xenofus oocites model 
(an Asiatic frog having a predominance of nicotinic 
acetylcholine receptors (nAChR)), using different 
anaesthetics, showed that the main inhibitor of 
these channels was the standard one. Ketamine 
competitively inhibited channel opening at ganglion 
level (predominantly on α4β2 receptors); the α4β4 
subunit has been the substrate for action in the 
Xenofus oocites model for nitrous oxide, propofol 
and xenon. The MOA for etomidate and thiopental 
is little known since no major effect on acetylcholine 
receptors has been found to date.5-31-32
Classifying anaesthetics according to 
action site
Anaesthetics’ MOA on different receptors in the 
CNS has meant that anaesthetics can be classified 
according to their site de action, thereby correlating 
their essential clinical characteristics and their 
molecular target.
CoNCluSioN
Research carried out from the time of the Meyer-
Overton unitary theory up to genetic studies and 
advances in molecular biology have all been impor-
tant processes in describing and understanding the 
complex mechanisms occurring at molecular level in 
the CNS due to inhaled or intravenous anaesthetic 
drugs being used. Physiologically, the actions are 
very different and compromise different regions of 
the CNS: immobility at spinal medulla level, amne-
sia and lack of consciousness at cerebral level and 
autonomic responses in specific areas of the bulb 
and protuberance. All these actions are very spe-
cifically modulated to different degrees by different 
receptors (with their different subtypes) regarding 
the response caused by anaesthetics.3-5
Based on the foregoing, studying and being 
aware of the molecular basis of anaesthesia is of 
vital importance in understanding the physiological 
phenomena produced by anaesthetics and their 
applicability in clinical practice. The drugs affecting 
the CNS will be designed more rationally in the near 
future, having more specific and effective action and 
having fewer collateral effects.2 Remaining ignorant 
of molecular biology will make it impossible to take 
advantage of new discoveries in anaesthetic phar-
macology for using them in anaesthetic practice in 
the future. 
Anaesthesiologists recognising the importance 
of these molecular and biological implications of 
anaesthetics will have at their disposal knowledge 
of a wide range of medicaments to enable a more 
critical selection of more reliable drugs for each pa-
tient, thereby contributing towards making practice 
in anaesthesiology safer and more fascinating.
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